Israel’s Novocure (see here previously) announced that using its TTFields (Tumor Treating electrical Fields) technology in combination with other therapies, improved overall patient survival compared to standard therapies alone. https://www.novocure.com/novocure-announces-pivotal-lunar-study-in-non-small-cell-lung-cancer-met-primary-overall-survival-endpoint/

Technion Professor Yoram Palti has been awarded the Israel Prize in the Field of Entrepreneurship and Technological Innovation. Prof Palti founded Israel’s Novocure (see here previously) that developed a groundbreaking cancer treatment (especially brain cancer) using electric pulses. https://www.timesofisrael.com/yoram-palti-awarded-israel-prize-for-groundbreaking-cancer-treatment/ https://en.globes.co.il/en/article-novocure-uses-electrodes-to-treat-brain-tumors-1001120662

Friends of Israeli Professor Yoram Palti encouraged him to invent Novocure’s electrode treatment for aggressive brain tumors.  Now eight years after its first trials, two of Novocure’s original patients are still alive.  One of the trials was stopped as it … Continue reading →

Israel’s Novocure was featured recently on ABC 10 News, which showed Novocure’s TTFields helmet being used to keep a San Diego brain cancer sufferer alive. Novocure is soon to trial TTFields on other solid cancers and has just filed for … Continue reading →

Three Israeli companies were chosen by the World Economic Forum (WEF) in its 2015 list of 14 Technology Pioneers in the Life Science and Health category. ElMindA’s Brain Network Activation identifies brain damage. Consumer Physics’s SCIO is a chemical analyzer. … Continue reading →

(Thanks to Israel21c) Here is a new report about the TTFields scalp device from Israel’s Novocure that slows the growth of brain tumors.  (Previously reported in Nov 2014). http://www.israel21c.org/headlines/wearable-device-slows-brain-tumor-growth/ https://www.youtube.com/watch?v=BL-3JkQOsPg

Israel’s Novocure has announced that its NovoTTF-100A portable scalp device extends the life of brain cancer patients. The device creates an alternating electric field and has had significant success in Phase 3 trials with patients receiving chemotherapy only. http://www.haaretz.com/life/science-medicine/1.626964

Israeli biotech Novocure’s clinical study of its NovoTTF therapy for pancreatic cancer demonstrated a significant decrease in cell count and reduced tumor volume. Its effectiveness was enhanced when combined with chemotherapy. http://www.pancreatology.net/article/S1424-3903%2813%2900844-2/abstract